Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Pyrotinib|DRUG: Trastuzumab|DRUG: Dalpiciclib|DRUG: Letrozole|DRUG: Pertuzumab|DRUG: Docetaxel|DRUG: Carboplatin|DRUG: Gonadotropin-releasing hormone agonist
Sponsor: Shengjing Hospital